Ok, bit more research. It IS the MSB cell that is being tested in Japan. JCR are developing JR-031 which is MSC-100-IV which is the product referenced in the February press release. Seems odd that all of their oncology product section refers to the Osiris product.
As for whether you might expect more optimal results - the results from Feb are OK, but then, the Osiris product works in paediatrics. The question is perhaps whether it works in adults. No way of knowing.
Also makes you wonder why they bought Osiris at all, though it was at a bargain basement price, considering the amount of money that Osiris had invested in the programme to that time.
Speculation on Japanese revenue stream, page-13
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.055(4.66%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.18 | $1.13 | $4.824M | 4.236M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25589 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |